Hyperkalemia is a diseases in which levels of potassium are higher than normal level in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating its excretion as well as its intake. A person is prone to develop hyperkalemia when the consumption of potassium exceeds that of kidney’s potential to excrete it.
On the basis of geography, the global Hyperkalemia Treatment Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global hyperkalemia treatment market followed by Europe during the forecast period.
Major Players in the Hyperkalemia Treatment Industry:
1) AstraZeneca Plc.
AstraZeneca Plc. Is a multinational pharmaceutical and biotechnology company. The company is known for manufacturing products for major diseases like Oncology, Cardiovascular, Infection, Respiratory and Inflammation. Apart from that, it has also been a part of developing the Oxford-AstraZeneca Covid-19 vaccine. The company was founded in 1999 and the headquarters are located in Cambridge, England, UK.
In July of 2021 AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc. In January of 2023, AstraZeneca also announced its plans to acquired CinCor a biopharmaceutical company based in the U.S.
2) Eli Lilly and Company
Eli Lilly and Company is an American pharmaceutical company. The products manufactured are sold in approximately 120 countries. The company is known for its clinical depression drugs Prozac, Cymbalta, and its antipsychotic medication Zyprexa. The company was founded in the year 1876, and the headquarters are located in Indianapolis, Indiana. The company was founded by Eli Lily.
